Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

c-Met Inhibitor MSC2156119J

Known as: MSC2156119J 
An orally bioavailable inhibitor of the proto-oncogene c-Met (also known as hepatocyte growth factor receptor (HGFR)) with potential antineoplastic… Expand
National Institutes of Health

Related topics

Related topics

1 relation
Receptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Efficacy, safety, biomarkers, and phase II dose modeling in a phase I trial of the oral selective c-Met inhibitor tepotinib (MSC2156119J).
2591 Background: Tumor c-Met overexpression is associated with tumor aggression and poor prognosis, making it a target for… Expand
2015
2015
P-118Tepotinib (MSC2156119J) monotherapy in patients with MET-positive advanced hepatocellular carcinoma with Child-Pugh Class A liver function who have failed sorafenib treatment: phase Ib/II trial
 
2015
2015
Abstract 4510: Model-based phase II dose selection of c-Met inhibitor MSC2156119J
Objectives: To evaluate the dose/exposure/target inhibition/tumor growth relationship of MSC2156119J, an orally administered… Expand
2015
2015
2353 Data from a phase Ib/II trial of the oral c-Met inhibitor tepotinib (MSC2156119J) as first-line therapy in Asian patients with advanced hepatocellular carcinoma
s S453 tepotinib (MSC2156119J) demonstrated promising antitumor activity in a phase I trial. Pharmacokinetic/pharmacodynamic… Expand
  • table 1
2014
2014
The c-Met Inhibitor MSC2156119J Effectively Inhibits Tumor Growth in Liver Cancer Models
The mesenchymal-epithelial transition factor (c-Met) is a receptor tyrosine kinase with hepatocyte growth factor (HGF) as its… Expand
  • figure 3
  • table 1
2014
2014
Results of the first-in-human phase I trial assessing MSC2156119J (EMD 1214063), an oral selective c-Met inhibitor, in patients (pts) with advanced solid tumors.
2521^ Background: MSC2156119J, a selective c-Met inhibitor, suppresses tumor growth in preclinical models. Methods: Primary… Expand
2014
2014
A multicenter, randomized, phase Ib/II trial of the oral c-Met inhibitor MSC2156119J as monotherapy versus sorafenib in Asian patients with MET-positive (MET+) advanced hepatocellular carcinoma (HCC…
TPS4151 Background: Patients (pts) with HCC have a poor prognosis. Effective treatments are limited, particularly in Asia, which… Expand
2014
2014
745TiPPHASE IB/II, MULTICENTER, SINGLE-ARM TRIAL OF THE ORAL C-MET INHIBITOR MSC2156119J AS MONOTHERAPY IN PATIENTS WITH MET-POSITIVE ADVANCED HEPATOCELLULAR CARCINOMA WITH CHILD-PUGH CLASS A LIVER…
ABSTRACT Background: Sorafenib remains the only approved systemic first-line medical treatment for advanced hepatocellular… Expand
2014
2014
Abstract CT236: MSC2156119J (EMD 1214063), an oral selective c-Met inhibitor, in patients with advanced solid tumors: results of the first-in-human phase I trial
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA Introduction: Overexpression of the c-Met oncoprotein can… Expand
2014
2014
450PDFIRST-IN-HUMAN PHASE I TRIAL ASSESSING THE HIGHLY SELECTIVE C-MET INHIBITOR MSC2156119J (EMD 1214063) IN PATIENTS WITH ADVANCED SOLID TUMORS.
ABSTRACT Aim: c-Met overexpression is associated with poor clinical prognosis. This dose-escalation study (3 + 3 design… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE